Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. [electronic resource]
Producer: 20101207Description: S20-7 p. digitalISSN:- 1533-7294
- Adamantane -- analogs & derivatives
- Aged
- Blood Glucose -- drug effects
- Diabetes Mellitus, Type 2 -- drug therapy
- Dipeptides -- therapeutic use
- Dipeptidyl-Peptidase IV Inhibitors -- adverse effects
- Exenatide
- Female
- Glucagon -- metabolism
- Glucagon-Like Peptide 1 -- agonists
- Glucagon-Like Peptide-1 Receptor
- Glycated Hemoglobin -- metabolism
- Humans
- Hypoglycemia
- Hypoglycemic Agents -- adverse effects
- Incretins -- adverse effects
- Insulin -- metabolism
- Liraglutide
- Male
- Metformin -- adverse effects
- Middle Aged
- Peptides -- therapeutic use
- Pyrazines -- therapeutic use
- Receptors, Glucagon
- Risk
- Sitagliptin Phosphate
- Triazoles -- therapeutic use
- Venoms -- therapeutic use
- Weight Loss
No physical items for this record
Publication Type: Case Reports; Journal Article
There are no comments on this title.
Log in to your account to post a comment.